查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2026753

毒性藥物篩檢市場預測至2034年—按類型、測試類型、技術、最終用戶和地區分類的全球分析

Toxicology Drug Screening Market Forecasts to 2034 - Global Analysis By Type, Test Type, Technology, End User and by Geography
出版日期: | 出版商: Stratistics Market Research Consulting | 英文 | 商品交期: 2-3個工作天內

價格

根據 Stratistics MRC 的數據，預計到 2026 年，全球毒理學篩檢市場規模將達到 180 億美元，並在預測期內以 10.7% 的複合年成長率成長，到 2034 年將達到 406 億美元。

藥物毒性篩檢是醫學診斷的重要組成部分，它涉及檢測血液、尿液和毛髮等生物檢體中的藥物及其代謝物。該程序在許多情況下都不可或缺，包括職場檢測、法醫學調查和臨床評估。此外，藥物毒性篩檢利用層析法-質譜聯用和免疫檢測等先進分析技術，可以檢測多種物質，包括毒素、非法藥物和處方藥。

根據國際藥品製造商協會聯合會 (IFPMA) 2021 年的報告，生物製藥產業的年度研發支出是航太和國防產業的 7.3 倍，是化學產業的 6.5 倍，是軟體和電腦服務產業的 1.5 倍。

藥物濫用增加

推動毒性藥物篩檢市場發展的主要因素之一是藥物濫用事件的不斷增加，這其中既包括傳統藥物，也包括新開發的合成物質。此外，尤其是在鴉片類藥物危機之後，人們比以往任何時候都更需要高效的篩檢方法來識別和治療藥物濫用。為了應對這些因素，市場正在開發能夠檢測多種物質（包括新型合成藥物）的新型調查方法，這些新合成藥物對現有的篩檢技術提出了挑戰。

辨識新物質的困難

新型藥物和新型精神活性物質（NPS）的快速出現，不斷為傳統的毒理學篩檢技術帶來挑戰，建構了一項重大障礙。隨著藥物濫用情勢的變化，篩檢方法難以跟上非法藥物成分動態變化的步伐。此外，透過持續的研發來加強篩檢能力，對於檢測新型化合物至關重要。

尖端篩檢技術的開發

開發更先進、更全面的篩檢技術具有巨大潛力。持續進行質譜和層析法等分析技術的研究與開發，可以提高靈敏度和特異性，並增強檢測更多種類物質的能力。此外，投資最尖端科技將使相關人員能夠更準確、更有效率地應對毒理學篩檢不斷變化的需求。

合成藥物的快速發展

新型藥物和新型精神藥物（NPS）的出現對現有的毒理學篩檢技術構成了嚴重威脅。這些物質的演變速度極快，使得篩檢測試難以辨識和檢測出新的化合物。此外，這還可能導致假陰性結果，從而降低藥物檢測的有效性。

新冠疫情的影響：

新冠疫情透過改變醫療保健的優先事項和流程，對藥物篩檢市場產生了重大影響。應對公共衛生緊急事件的重心分散，導致藥物檢測項目和其他常規醫療保健服務中斷。儘管藥物篩檢的需求依然存在，尤其是在關鍵職位和急診科，但疫情為檢體採集、檢查室操作和整體物流帶來了許多困難。此外，疫情期間的預算限制和經濟不確定性也影響了對尖端毒理學技術的投資決策。

在預測期內，心血管疾病藥物篩檢領域預計將是規模最大的領域。

預計心血管疾病藥物篩檢領域將佔據最大的市場佔有率。心血管疾病是全球發病率和死亡率的主要原因，其中包括血脂異常症和高血壓等疾病。因此，藥物研發最重要的方面之一就是心血管疾病藥物篩檢。此外，識別針對血壓、膽固醇和凝血因子等心血管健康風險因子的藥物和治療方法，是心血管疾病藥物篩檢市場的核心。

在預測期內，診斷檢查室領域預計將呈現最高的複合年成長率。

在整個預測期內，診斷檢查室領域預計將呈現最高的複合年成長率。診斷檢查室提供種類繁多的疾病診斷和後續觀察檢測，使其成為醫療保健流程中不可或缺的一部分。此外，慢性病盛行率的不斷上升和診斷技術的進步正在推動對先進檢測服務的需求。診斷實驗室在精準醫療和個人化醫療中發揮關鍵作用，並且與製藥公司和醫療保健機構建立了合作關係，這些都為其在該市場的持續成長奠定了堅實的基礎。

市佔率最大的地區：

預計北美將佔據最大的市場佔有率。這一主導地位歸功於多種因素，包括對研發的大量投入、完善的診斷檢查室網路、慢性病高發以及先進的醫療基礎設施。特別是美國，憑藉其強大的醫療保健系統和診斷技術的不斷進步，成為市場成長的主要驅動力。此外，該地區對個人化和精準醫療的重視也是北美持續主導診斷檢查室市場的重要因素。

複合年成長率最高的地區：

受先進診斷服務需求成長、健康意識提升以及感染疾病和慢性病流行等因素的推動，亞太地區診斷檢查室市場預計將以最高的複合年成長率成長。除了診斷技術的顯著進步外，中國、印度和日本等國家也大力投資醫療基礎建設。此外，亞太地區診斷檢查室市場的強勁成長也得益於各國對醫療保健的日益重視以及精準醫療實踐的廣泛應用。

免費客製化服務：

所有購買此報告的客戶均可享受以下免費自訂選項之一：

  • 企業概況
    • 對其他市場參與者（最多 3 家公司）進行全面分析
    • 對主要公司進行SWOT分析（最多3家公司）
  • 區域分類
    • 應客戶要求，我們提供主要國家和地區的市場估算和預測，以及複合年成長率（註：需進行可行性檢查）。
  • 競爭性標竿分析
    • 根據產品系列、地理覆蓋範圍和策略聯盟對重點公司進行基準分析。

目錄

第1章執行摘要

第2章：引言

  • 概括
  • 相關利益者
  • 調查範圍
  • 調查方法
  • 研究材料

第3章 市場趨勢分析

  • 促進因素
  • 抑制因子
  • 機會
  • 威脅
  • 技術分析
  • 最終用戶分析
  • 新興市場
  • 新冠疫情的感染疾病

第4章：波特五力分析

  • 供應商的議價能力
  • 買方的議價能力
  • 替代品的威脅
  • 新進入者的威脅
  • 競爭公司之間的競爭

第5章 全球毒性藥物篩檢市場：按類型分類

  • 心血管疾病藥物篩檢
  • 肥胖症藥物篩檢
  • 糖尿病藥物篩檢
  • 其他類型

第6章 全球毒理學篩檢市場：依檢測類型分類

  • 急性全身毒性
  • 經皮毒性
  • 致癌性
  • 眼毒性
  • 基因毒性
  • 神經毒性
  • 器官特異性毒性
  • 其他測試類型

第7章 全球毒性藥物篩檢市場：依技術分類

  • 高通量篩檢
  • 基因組學
  • 轉錄組學
  • 毒理基因組學
  • 分子篩檢
  • 其他技術

第8章 全球毒性藥物篩檢市場：依最終用戶分類

  • 醫院與創傷中心
  • 法醫學研究所
  • 診斷檢查室
  • 復健中心
  • 製藥和生物技術公司
  • 其他最終用戶

第9章 全球毒性藥物篩檢市場：依地區分類

  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 德國
    • 英國
    • 義大利
    • 法國
    • 西班牙
    • 其他歐洲國家
  • 亞太地區
    • 日本
    • 中國
    • 印度
    • 澳洲
    • 紐西蘭
    • 韓國
    • 其他亞太國家
  • 南美洲
    • 阿根廷
    • 巴西
    • 智利
    • 其他南美國家
  • 中東和非洲
    • 沙烏地阿拉伯
    • UAE
    • 卡達
    • 南非
    • 其他中東和非洲國家

第10章 主要發展

  • 合約、夥伴關係、合作關係、合資企業
  • 收購與併購
  • 新產品發布
  • 業務拓展
  • 其他關鍵策略

第11章：公司簡介

  • Covance, Inc.
  • Agilent Technologies Inc.
  • Enzo Life Sciences Inc.
  • Danaher
  • Alere, Inc.
  • BioReliance, Inc.
  • Eurofins Scientific
  • Bio-Rad Laboratories Inc.
  • Promega Corporation
  • GE Healthcare
  • Thermo Fisher Scientific Inc.
  • Charles River Laboratories International Inc.
Product Code: SMRC24564

According to Stratistics MRC, the Global Toxicology Drug Screening Market is accounted for $18.0 billion in 2026 and is expected to reach $40.6 billion by 2034 growing at a CAGR of 10.7% during the forecast period. One essential part of medical diagnostics is toxicology drug screening, which looks for drugs or their metabolites in biological samples like blood, urine, or hair. In a number of contexts, such as workplace testing, forensic investigations, and clinical evaluations, this procedure is essential. Moreover, toxicology drug screening can detect a variety of substances, including toxins, illicit drugs, and prescription medications, by using advanced analytical techniques like chromatography-mass spectrometry and immunoassays.

According to the IFPMA's 2021 report, the annual R&D spending by the biopharmaceutical industry is 7.3 times higher than that of the aerospace and defense industries, 6.5 times more than the chemicals industry, and 1.5 times more than the software and computer services industry.

Market Dynamics:

Driver:

Growing number of cases of substance abuse

One of the main factors propelling the toxicology drug screening market is the rising incidence of substance abuse, which includes both conventional drugs and newly developed synthetic substances. Additionally, particularly in light of the opioid crisis, there is a greater need than ever for efficient screening methods that identifies and treats drug abuse. In response to this driver, the market has developed novel testing methodologies that can detect a wide range of substances, including new designer drugs that present challenges to established screening techniques.

Restraint:

Difficulties in identifying novel substances

The quick rise of designer drugs and new psychoactive substances (NPS), which continuously complicate conventional toxicology screening techniques, is one major barrier. As the world of substance abuse changes, screening assays find it challenging to keep up with the dynamic nature of illicit drug formulations. Furthermore, enhancing screening capabilities through ongoing research and development is necessary to adjust to the detection of novel compounds.

Opportunity:

Development of cutting-edge screening technologies

The development of more sophisticated and all-encompassing screening technologies has a great deal of potential. Improved sensitivity, specificity, and the capacity to detect a wider variety of substances can result from ongoing research and innovation in analytical techniques like mass spectrometry and chromatography. Moreover, putting money into state-of-the-art technologies puts stakeholders in a position to more accurately and efficiently handle the changing demands of toxicology screening.

Threat:

Designer drugs quick evolution

The development of designer drugs and novel psychoactive substances (NPS) presents a serious threat to established toxicology screening techniques. These substances are evolving quickly, which makes it difficult for screening assays to identify and detect new compounds. Additionally, this could result in false negative results and reduce the effectiveness of drug testing.

Covid-19 Impact:

The COVID-19 pandemic has had a profound effect on the market for toxicology drug screening, changing healthcare priorities and procedures. Drug testing programs and other regular healthcare services have been disrupted as a result of the focus on solving the public health emergency. Although there was still a need for toxicology screening, especially for critical workers and in emergency rooms, the pandemic created difficulties for sample collection, laboratory operations, and general logistics. Furthermore, decisions to invest in cutting-edge toxicology technologies were influenced by budgetary constraints and economic uncertainties during the pandemic.

The Cardiovascular Disease Drug Screening segment is expected to be the largest during the forecast period

The cardiovascular disease drug screening segment is projected to hold the largest share. The world's leading causes of morbidity and mortality are cardiovascular diseases, which include ailments like dyslipidemia and hypertension. Thus, one of the most important aspects of pharmaceutical research and development is drug screening for cardiovascular diseases. Moreover, the identification of drugs and treatments that target heart and vascular health risk factors, such as blood pressure, cholesterol, and clotting factors, is central to the cardiovascular drug screening market.

The Diagnostic Laboratories segment is expected to have the highest CAGR during the forecast period

Over the course of the forecast period, the diagnostic laboratories segment is expected to have the highest CAGR. Diagnostic laboratories offer a wide variety of tests for the diagnosis and monitoring of diseases, which makes them essential to the healthcare process. Additionally, the need for advanced testing services has increased due to the rising prevalence of chronic conditions and the development of diagnostic technologies. Due to their crucial role in precision and personalized medicine, as well as their partnerships with pharmaceutical companies and healthcare providers, diagnostic laboratories are well-positioned for continued growth in this market.

Region with largest share:

North America is expected to hold the largest share. Many factors contribute to this prominence, including substantial investments in research and development, a well-established network of diagnostic laboratories, a high prevalence of chronic diseases, and an advanced healthcare infrastructure. The United States, in particular, is a major factor driving market growth because of its strong healthcare system and ongoing advancements in diagnostic technology. Furthermore, North America continues to dominate the market for diagnostic laboratories, in part because of the region's emphasis on personalized healthcare and precision medicine.

Region with highest CAGR:

The diagnostic laboratories market is expected to grow at the highest CAGR in the Asia-Pacific (APAC) region, due to factors such as growing demand for advanced diagnostic services, rising healthcare awareness, and the prevalence of infectious and chronic diseases. Alongside significant advancements in diagnostic technologies, nations like China, India, and Japan are investing heavily in their healthcare infrastructure. Moreover, the region's strong growth in the diagnostic laboratory market is also attributed to the emphasis on preventive healthcare and the adoption of precision medicine practices in several APAC countries.

Key players in the market

Some of the key players in Toxicology Drug Screening market include Covance, Inc., Agilent Technologies Inc., Enzo Life Sciences Inc., Danaher, Alere, Inc., BioReliance, Inc., Eurofins Scientific, Bio-Rad Laboratories Inc., Promega Corporation, GE Healthcare, Thermo Fisher Scientific Inc and Charles River Laboratories International Inc.

Key Developments:

In November 2023, Danaher will acquire all of the outstanding shares of Abcam for $24 per share in cash, for a total enterprise value of approximately $5.7bn including assumed indebtedness and net of acquired cash.

In September 2023, Agilent Technologies Inc. (NYSE: A) recently signed a Research Collaboration Agreement (RCA) with the National Cancer Centre Singapore (NCCS) outlining their collaboration to accelerate translational cancer research on the genomic landscape of Asian-prevalent cancers over the next two years.

In July 2023, Bio-Rad Laboratories, Inc. and QIAGEN N.V., today announced that the companies have agreed to settle their patent dispute pending in the U.S. District Court of Delaware pursuant to a global settlement and patent cross-licensing agreement relating to digital PCR technology.

Types Covered:

  • Cardiovascular Disease Drug Screening
  • Obesity Drug Screening
  • Diabetes Drug Screening
  • Other Types

Test Types Covered:

  • Acute Systemic Toxicity
  • Dermal Toxicity
  • Carcinogenicity
  • Ocular Toxicity
  • Genotoxicity
  • Neurotoxicity
  • Organ-Specific Toxicity
  • Other Test Types

Technologies Covered:

  • High-Throughput Screening
  • Genomics
  • Transcriptomics
  • Toxicogenomics
  • Molecular Screening
  • Other Technologies

End Users Covered:

  • Hospitals and Trauma Centers
  • Forensic Laboratories
  • Diagnostic Laboratories
  • Rehabilitation Centers
  • Pharmaceutical & Biotechnology Companies
  • Other End Users

Regions Covered:

  • North America
    • US
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • Italy
    • France
    • Spain
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • New Zealand
    • South Korea
    • Rest of Asia Pacific
  • South America
    • Argentina
    • Brazil
    • Chile
    • Rest of South America
  • Middle East & Africa
    • Saudi Arabia
    • UAE
    • Qatar
    • South Africa
    • Rest of Middle East & Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2023, 2024, 2025, 2026, 2027, 2028, 2030, 2032 and 2034
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

  • 2.1 Abstract
  • 2.2 Stake Holders
  • 2.3 Research Scope
  • 2.4 Research Methodology
    • 2.4.1 Data Mining
    • 2.4.2 Data Analysis
    • 2.4.3 Data Validation
    • 2.4.4 Research Approach
  • 2.5 Research Sources
    • 2.5.1 Primary Research Sources
    • 2.5.2 Secondary Research Sources
    • 2.5.3 Assumptions

3 Market Trend Analysis

  • 3.1 Introduction
  • 3.2 Drivers
  • 3.3 Restraints
  • 3.4 Opportunities
  • 3.5 Threats
  • 3.6 Technology Analysis
  • 3.7 End User Analysis
  • 3.8 Emerging Markets
  • 3.9 Impact of Covid-19

4 Porters Five Force Analysis

  • 4.1 Bargaining power of suppliers
  • 4.2 Bargaining power of buyers
  • 4.3 Threat of substitutes
  • 4.4 Threat of new entrants
  • 4.5 Competitive rivalry

5 Global Toxicology Drug Screening Market, By Type

  • 5.1 Introduction
  • 5.2 Cardiovascular Disease Drug Screening
  • 5.3 Obesity Drug Screening
  • 5.4 Diabetes Drug Screening
  • 5.5 Other Types

6 Global Toxicology Drug Screening Market, By Test Type

  • 6.1 Introduction
  • 6.2 Acute Systemic Toxicity
  • 6.3 Dermal Toxicity
  • 6.4 Carcinogenicity
  • 6.5 Ocular Toxicity
  • 6.6 Genotoxicity
  • 6.7 Neurotoxicity
  • 6.8 Organ-Specific Toxicity
  • 6.9 Other Test Types

7 Global Toxicology Drug Screening Market, By Technology

  • 7.1 Introduction
  • 7.2 High-Throughput Screening
  • 7.3 Genomics
  • 7.4 Transcriptomics
  • 7.5 Toxicogenomics
  • 7.6 Molecular Screening
  • 7.7 Other Technologies

8 Global Toxicology Drug Screening Market, By End User

  • 8.1 Introduction
  • 8.2 Hospitals and Trauma Centers
  • 8.3 Forensic Laboratories
  • 8.4 Diagnostic Laboratories
  • 8.5 Rehabilitation Centers
  • 8.6 Pharmaceutical & Biotechnology Companies
  • 8.7 Other End Users

9 Global Toxicology Drug Screening Market, By Geography

  • 9.1 Introduction
  • 9.2 North America
    • 9.2.1 US
    • 9.2.2 Canada
    • 9.2.3 Mexico
  • 9.3 Europe
    • 9.3.1 Germany
    • 9.3.2 UK
    • 9.3.3 Italy
    • 9.3.4 France
    • 9.3.5 Spain
    • 9.3.6 Rest of Europe
  • 9.4 Asia Pacific
    • 9.4.1 Japan
    • 9.4.2 China
    • 9.4.3 India
    • 9.4.4 Australia
    • 9.4.5 New Zealand
    • 9.4.6 South Korea
    • 9.4.7 Rest of Asia Pacific
  • 9.5 South America
    • 9.5.1 Argentina
    • 9.5.2 Brazil
    • 9.5.3 Chile
    • 9.5.4 Rest of South America
  • 9.6 Middle East & Africa
    • 9.6.1 Saudi Arabia
    • 9.6.2 UAE
    • 9.6.3 Qatar
    • 9.6.4 South Africa
    • 9.6.5 Rest of Middle East & Africa

10 Key Developments

  • 10.1 Agreements, Partnerships, Collaborations and Joint Ventures
  • 10.2 Acquisitions & Mergers
  • 10.3 New Product Launch
  • 10.4 Expansions
  • 10.5 Other Key Strategies

11 Company Profiling

  • 11.1 Covance, Inc.
  • 11.2 Agilent Technologies Inc.
  • 11.3 Enzo Life Sciences Inc.
  • 11.4 Danaher
  • 11.5 Alere, Inc.
  • 11.6 BioReliance, Inc.
  • 11.7 Eurofins Scientific
  • 11.8 Bio-Rad Laboratories Inc.
  • 11.9 Promega Corporation
  • 11.10 GE Healthcare
  • 11.11 Thermo Fisher Scientific Inc.
  • 11.12 Charles River Laboratories International Inc.

List of Tables

  • Table 1 Global Toxicology Drug Screening Market Outlook, By Region (2023-2034) ($MN)
  • Table 2 Global Toxicology Drug Screening Market Outlook, By Type (2023-2034) ($MN)
  • Table 3 Global Toxicology Drug Screening Market Outlook, By Cardiovascular Disease Drug Screening (2023-2034) ($MN)
  • Table 4 Global Toxicology Drug Screening Market Outlook, By Obesity Drug Screening (2023-2034) ($MN)
  • Table 5 Global Toxicology Drug Screening Market Outlook, By Diabetes Drug Screening (2023-2034) ($MN)
  • Table 6 Global Toxicology Drug Screening Market Outlook, By Other Types (2023-2034) ($MN)
  • Table 7 Global Toxicology Drug Screening Market Outlook, By Test Type (2023-2034) ($MN)
  • Table 8 Global Toxicology Drug Screening Market Outlook, By Acute Systemic Toxicity (2023-2034) ($MN)
  • Table 9 Global Toxicology Drug Screening Market Outlook, By Dermal Toxicity (2023-2034) ($MN)
  • Table 10 Global Toxicology Drug Screening Market Outlook, By Carcinogenicity (2023-2034) ($MN)
  • Table 11 Global Toxicology Drug Screening Market Outlook, By Ocular Toxicity (2023-2034) ($MN)
  • Table 12 Global Toxicology Drug Screening Market Outlook, By Genotoxicity (2023-2034) ($MN)
  • Table 13 Global Toxicology Drug Screening Market Outlook, By Neurotoxicity (2023-2034) ($MN)
  • Table 14 Global Toxicology Drug Screening Market Outlook, By Organ-Specific Toxicity (2023-2034) ($MN)
  • Table 15 Global Toxicology Drug Screening Market Outlook, By Other Test Types (2023-2034) ($MN)
  • Table 16 Global Toxicology Drug Screening Market Outlook, By Technology (2023-2034) ($MN)
  • Table 17 Global Toxicology Drug Screening Market Outlook, By High-Throughput Screening (2023-2034) ($MN)
  • Table 18 Global Toxicology Drug Screening Market Outlook, By Genomics (2023-2034) ($MN)
  • Table 19 Global Toxicology Drug Screening Market Outlook, By Transcriptomics (2023-2034) ($MN)
  • Table 20 Global Toxicology Drug Screening Market Outlook, By Toxicogenomics (2023-2034) ($MN)
  • Table 21 Global Toxicology Drug Screening Market Outlook, By Molecular Screening (2023-2034) ($MN)
  • Table 22 Global Toxicology Drug Screening Market Outlook, By Other Technologies (2023-2034) ($MN)
  • Table 23 Global Toxicology Drug Screening Market Outlook, By End User (2023-2034) ($MN)
  • Table 24 Global Toxicology Drug Screening Market Outlook, By Hospitals and Trauma Centers (2023-2034) ($MN)
  • Table 25 Global Toxicology Drug Screening Market Outlook, By Forensic Laboratories (2023-2034) ($MN)
  • Table 26 Global Toxicology Drug Screening Market Outlook, By Diagnostic Laboratories (2023-2034) ($MN)
  • Table 27 Global Toxicology Drug Screening Market Outlook, By Rehabilitation Centers (2023-2034) ($MN)
  • Table 28 Global Toxicology Drug Screening Market Outlook, By Pharmaceutical & Biotechnology Companies (2023-2034) ($MN)
  • Table 29 Global Toxicology Drug Screening Market Outlook, By Other End Users (2023-2034) ($MN)

Note: Tables for North America, Europe, APAC, South America, and Middle East & Africa Regions are also represented in the same manner as above.